medigraphic.com
ISSN 0326-3428 (Print)
Órgano de difusión científica de la Asociación Nefrológica de Buenos Aires

2025, Number 3

<< Back Next >>

Rev Nefrol Dial Traspl 2025; 45 (3)

Ferric Carboxymaltose reduces NT-proBNP and enhances functional status in chronic kidney disease and heart failure with preserved ejection fraction

Helvacı Ö, Yıldırım S, Yasar E, Demirezen A, Faruk AO, Altok K, Erten Y, Guz G, Derici U, Sezenoz B, Seckin O, Isil AE

Language: English
References: 23
Page: 146-152
PDF size: 258.41 Kb.


ABSTRACT

Introduction: Heart failure with preserved ejection fraction (HFpEF) accounts for approximately half of all heart failure cases and frequently coexists with chronic kidney disease (CKD), particularly in advanced stages. Iron deficiency is highly prevalent in both conditions and contributes to impaired functional capacity and adverse outcomes. Objectives: To evaluate the effect of a single intravenous ferric carboxymaltose (FCM) dose on NT-proBNP levels and NYHA class in non-dialysis CKD patients with HFpEF and iron deficiency anemia, and to assess the short-term renal safety of this intervention. Materials and Methods: In this prospective cohort study, 45 adults with stage 2–5 non-dialysis CKD, LVEF ≥50%, and NTproBNP ≥1000 pg/mL received a single FCM infusion (500–1000 mg). We measured clinical, echocardiographic, hematologic, renal, and iron parameters at baseline and one month posttreatment. Results: NT-proBNP levels declined significantly from 3924±5841 to 2187±3652 pg/ mL (p‹0.001), representing a 44.3% reduction. NYHA class improved in 42% of patients (p=0.034). No significant change was observed in eGFR (33±17 to 34±16 mL/min/1.73 m², p=0.864). Iron parameters and hemoglobin levels improved significantly without infusion-related adverse events. Conclusions: Single-dose IV iron therapy in HFpEF patients with CKD was associated with significant NT-proBNP reduction and functional improvement, without evidence of short-term renal harm. These findings support IV iron as a safe and potentially beneficial intervention in this underrepresented high-risk population.


REFERENCES

  1. Borlaug BA, Redfield MM. Diastolic andsystolic heart failure are distinct phenotypeswithin the heart failure spectrum. Circulation. 2011;123(18):2006-13; discussion 14.

  2. Solomon SD, McMurray JJV, Claggett B, deBoer RA, DeMets D, Hernandez AF, et al.Dapagliflozin in Heart Failure with MildlyReduced or Preserved Ejection Fraction. NEngl J Med. 2022;387(12):1089-98.

  3. Anker SD, Butler J, Filippatos G, FerreiraJP, Bocchi E, Bohm M, et al. Empagliflozinin Heart Failure with a Preserved EjectionFraction. N Engl J Med. 2021;385(16):1451-61.

  4. Solomon SD, McMurray JJV, VaduganathanM, Claggett B, Jhund PS, Desai AS, et al.Finerenone in Heart Failure with MildlyReduced or Preserved Ejection Fraction. NEngl J Med. 2024;391(16):1475-85.

  5. Lofman I, Szummer K, Dahlstrom U,Jernberg T, Lund LH. Associations with andprognostic impact of chronic kidney diseasein heart failure with preserved, mid-range,and reduced ejection fraction. Eur J HeartFail. 2017;19(12):1606-14.

  6. Cobo Marcos M, de la Espriella R, GayanOrdas J, Llacer P, Pomares A, Fort A, et al.Prevalence and clinical profile of kidneydisease in patients with chronic heart failure.Insights from the Spanish cardiorenal registry.Rev Esp Cardiol (Engl Ed). 2024;77(1):50-9.

  7. Malik J, Valerianova A, Pesickova SS,Michalickova K, Hladinova Z, Hruskova Z,et al. Heart failure with preserved ejectionfraction is the most frequent but commonlyoverlooked phenotype in patients on chronichemodialysis. Front Cardiovasc Med.2023;10:1130618.

  8. House AA, Wanner C, Sarnak MJ, Pina IL,McIntyre CW, Komenda P, et al. Heart failurein chronic kidney disease: conclusions from aKidney Disease: Improving Global Outcomes(KDIGO) Controversies Conference. KidneyInt. 2019;95(6):1304-17.

  9. Jankowska EA, Rozentryt P, Witkowska A,Nowak J, Hartmann O, Ponikowska B, et al.Iron deficiency: an ominous sign in patientswith systolic chronic heart failure. Eur HeartJ. 2010;31(15):1872-80.

  10. Anker SD, Comin Colet J, Filippatos G,Willenheimer R, Dickstein K, Drexler H, etal. Ferric carboxymaltose in patients withheart failure and iron deficiency. N Engl JMed. 2009;361(25):2436-48.

  11. Ponikowski P, van Veldhuisen DJ, CominColet J, Ertl G, Komajda M, Mareev V, et al.Beneficial effects of long-term intravenousiron therapy with ferric carboxymaltosein patients with symptomatic heart failureand iron deficiency dagger. Eur Heart J.2015;36(11):657-68.

  12. Ponikowski P, Kirwan BA, Anker SD,McDonagh T, Dorobantu M, Drozdz J, et al.Ferric carboxymaltose for iron deficiencyat discharge after acute heart failure: amulticentre, double-blind, randomised,controlled trial. Lancet. 2020;396(10266):1895-904.

  13. McDonagh TA, Metra M, Adamo M, GardnerRS, Baumbach A, Bohm M, et al. 2021 ESCGuidelines for the diagnosis and treatment ofacute and chronic heart failure. Eur Heart J.2021;42(36):3599-726.

  14. von Haehling S, Doehner W, Evertz R,Garfias-Veitl T, Derad C, Diek M, et al. Ferriccarboxymaltose and exercise capacity in heartfailure with preserved ejection fraction andiron deficiency: the FAIR-HFpEF trial. EurHeart J. 2024;45(37):3789-800.

  15. Bettencourt P, Azevedo A, Pimenta J, FrioesF, Ferreira S, Ferreira A. N-terminal-pro-brainnatriuretic peptide predicts outcome afterhospital discharge in heart failure patients.Circulation. 2004;110(15):2168-74.

  16. Hoes MF, Grote Beverborg N, Kijlstra JD,Kuipers J, Swinkels DW, Giepmans BNG, etal. Iron deficiency impairs the contractilityof human cardiomyocytes through decreasedmitochondrial function. Eur J Heart Fail.2018;20(5):910-9.

  17. Alnuwaysir RIS, Hoes MF, van VeldhuisenDJ, van der Meer P, Grote Beverborg N. IronDeficiency in Heart Failure: Mechanisms andPathophysiology. J Clin Med. 2021;11(1).

  18. Toblli JE, Lombrana A, Duarte P, Di GennaroF. Intravenous iron reduces NT-pro-brainnatriuretic peptide in anemic patients withchronic heart failure and renal insufficiency. JAm Coll Cardiol. 2007;50(17):1657-65.

  19. Awad AK, Abdelgalil MS, Gonnah AR,Mouffokes A, Ahmad U, Awad AK, et al.Intravenous iron for acute and chronic heartfailure with reduced ejection fraction (HFrEF)patients with iron deficiency: An updatedsystematic review and meta-analysis. ClinMed (Lond). 2024;24(3):100211.

  20. Lindberg F, Lund LH, Benson L, Linde C,Orsini N, Carrero JJ, et al. Iron deficiencyin heart failure: screening, prevalence,incidence, and outcome data from the SwedishHeart Failure Registry and the StockholmCREAtinine Measurements collaborativeproject. Eur J Heart Fail. 2023;25(8):1270-80.

  21. McDonagh TA, Metra M, Adamo M,Gardner RS, Baumbach A, Bohm M, etal. 2023 Focused Update of the 2021 ESCGuidelines for the diagnosis and treatment ofacute and chronic heart failure. Eur Heart J.2023;44(37):3627-39.

  22. Macdougall IC, Bock AH, Carrera F, EckardtKU, Gaillard C, Van Wyck D, et al. FINDCKD:a randomized trial of intravenousferric carboxymaltose versus oral iron inpatients with chronic kidney disease and irondeficiency anaemia. Nephrol Dial Transplant.2014;29(11):2075-84.

  23. Agarwal R, Kusek JW, Pappas MK. Arandomized trial of intravenous and oraliron in chronic kidney disease. Kidney Int.2015;88(4):905-14.




2020     |     www.medigraphic.com